Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

Frederik Novak; Hamza Mahmood Bajwa; John Eugenio Coia; Anna Christine Nilsson; Christian Nielsen; Dorte K Holm; Kamilla Østergaard; Mathilde Vilhelmine Miller Hvidt; Keld-Erik Byg; Isik S Johansen; Kristen Mittl; William Rowles; Scott S Zamvil; Riley Bove; Joseph J Sabatino; Tobias Sejbaek

doi:10.1136/jnnp-2022-330757

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF

PDF +
Supplementary
Material

Multiple sclerosis

Short report

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

Online download statistics by month:

Online download statistics by month: April 2023 to October 2023

	Abstract	Full	Pdf
Apr 2023	257	254	44
May 2023	861	844	122
Jun 2023	553	553	27
Jul 2023	447	444	20
Aug 2023	614	609	32
Sep 2023	596	598	42
Oct 2023	612	620	54
Total	3940	3922	341

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: April 2023 to October 2023

Read the full text or download the PDF:

Log in using your username and password